- Home
- DAWN vs LTC Comparison
DAWN vs LTC Comparison
Compare DAWN & LTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DAWN | LTC |
|---|---|---|
| Founded | 2018 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 2021 | 1994 |
Fundamental Metrics
Financial Performance| Metric | DAWN | LTC |
|---|---|---|
| Price | $21.50 | $38.57 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 8 | 5 |
| Target Price | $24.43 | ★ $40.00 |
| AVG Volume (30 Days) | ★ 2.7M | 313.7K |
| Earning Date | 05-01-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 5.96% |
| EPS Growth | N/A | ★ 23.53 |
| EPS | N/A | ★ 0.48 |
| Revenue | $158,182,000.00 | ★ $262,854,000.00 |
| Revenue This Year | $55.03 | N/A |
| Revenue Next Year | $28.12 | N/A |
| P/E Ratio | ★ N/A | $80.21 |
| Revenue Growth | 20.60 | ★ 25.26 |
| 52 Week Low | $5.64 | $33.64 |
| 52 Week High | $21.53 | $40.80 |
Technical Indicators
Market Signals| Indicator | DAWN | LTC |
|---|---|---|
| Relative Strength Index (RSI) | 80.29 | 51.44 |
| Support Level | $10.30 | $38.48 |
| Resistance Level | N/A | $39.80 |
| Average True Range (ATR) | 0.03 | 0.63 |
| MACD | -0.28 | 0.02 |
| Stochastic Oscillator | 90.91 | 50.89 |
Price Performance
Historical ComparisonAbout DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.
About LTC LTC Properties Inc.
LTC Properties Inc is a real estate investment trust. It invests in seniors housing and health care properties, mainly through ownership, sale-leasebacks, mortgage financing, joint ventures, construction financing, and structured finance solutions, including preferred equity, bridge, and mezzanine lending. The company's investment portfolio comprises several properties located throughout the USA, the majority of which are seniors housing and skilled nursing properties. The firm conducts and manages its business as two operating segments: Real Estate Investments, which generates maximum revenue, and SHOP.